76 related articles for article (PubMed ID: 21778309)
1. Prognostic significance of angiogenic factors in uterine cervical cancer.
Landt S; Wehling M; Heidecke H; Jeschke S; Korlach S; Stöblen F; Schmid P; Blohmer JU; Lichtenegger W; Sehouli J; Kümmel S
Anticancer Res; 2011 Aug; 31(8):2589-95. PubMed ID: 21778309
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
Monk BJ; Willmott LJ; Sumner DA
Gynecol Oncol; 2010 Feb; 116(2):181-6. PubMed ID: 19861227
[TBL] [Abstract][Full Text] [Related]
3. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas.
Fujimoto J
Anticancer Res; 2009 Jul; 29(7):2665-9. PubMed ID: 19596943
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
Willmott LJ; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
[TBL] [Abstract][Full Text] [Related]
6. The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer.
Landt S; Heidecke H; Reuter C; Korlach S; Blohmer JU; Lichtenegger W; Heusner T; Stöblen F; Thill M; Barinoff J; Sehouli J; Kümmel S
Anticancer Res; 2011 Aug; 31(8):2645-9. PubMed ID: 21778317
[TBL] [Abstract][Full Text] [Related]
7. Tumor volume and uterine body invasion assessed by MRI for prediction of outcome in cervical carcinoma treated with concurrent chemotherapy and radiotherapy.
Kim H; Kim W; Lee M; Song E; Loh JJ
Jpn J Clin Oncol; 2007 Nov; 37(11):858-66. PubMed ID: 18037686
[TBL] [Abstract][Full Text] [Related]
8. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
9. [Tumour angiogenesis and therapy directed at the neovasculature].
Eikesdal HP; Dahl O; Straume O; Akslen LA
Tidsskr Nor Laegeforen; 2004 Aug; 124(15):1919-22. PubMed ID: 15306859
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Clin Cancer Res; 2001 Sep; 7(9):2826-31. PubMed ID: 11555600
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
12. Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer.
Fujimoto J; Alam SM; Jahan I; Sato E; Toyoki H; Hong BL; Sakaguchi H; Tamaya T
Cancer Sci; 2006 Sep; 97(9):861-7. PubMed ID: 16805819
[TBL] [Abstract][Full Text] [Related]
13. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer.
Güllü IH; Marangoz S
Br J Cancer; 1999 Aug; 80(11):1865. PubMed ID: 10468311
[No Abstract] [Full Text] [Related]
14. Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer.
Srivastava S; Gupta A; Agarwal GG; Natu SM; Uma S; Goel MM; Srivastava AN
Biosci Trends; 2009 Aug; 3(4):144-50. PubMed ID: 20103839
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in uterine cervical and corpus cancer].
Yoshioka T; Inoue Y; Hoshiai H; Noda K
Gan To Kagaku Ryoho; 1995 Sep; 22(10):1417-22. PubMed ID: 7668881
[TBL] [Abstract][Full Text] [Related]
16. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Crafton SM; Salani R
Clin Ther; 2016 Mar; 38(3):449-58. PubMed ID: 26926322
[TBL] [Abstract][Full Text] [Related]
17. [Morphological index for prediction of cervix uteri cancer].
Gatenadze TsZ; Ungiadze DIu; Chakhoian OP; Nakashidze MG; Sulaberidze IM
Georgian Med News; 2010 Jan; (178):20-6. PubMed ID: 20157201
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer.
Mabuchi S; Matsumoto Y; Isohashi F; Yoshioka Y; Ohashi H; Morii E; Hamasaki T; Aozasa K; Mutch DG; Kimura T
Gynecol Oncol; 2011 Jul; 122(1):25-32. PubMed ID: 21514632
[TBL] [Abstract][Full Text] [Related]
19. Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.
Hellberg D; Tot T; Stendahl U
Gynecol Oncol; 2009 Jan; 112(1):235-40. PubMed ID: 18976801
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
Alldredge JK; Tewari KS
Oncologist; 2016 May; 21(5):576-85. PubMed ID: 27026677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
